双価サイト1-サイト2リガンドによるインスリン受容体対抗性の構造的基礎
Amber Vogel1, Alan Blakely1, Yuankun Dao2
1Department of Biochemistry, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA.
bioRxiv : the preprint server for biology
|September 2, 2025
まとめ
生まれながらの高インスリン症 (HI) の治療は,インスリン受容体 (IR) 抗薬S961とIns- AC- S2がIRを結合する方法を理解することで進める可能性があります. リンガンドの構造によって,アゴニストかアンタゴニストとして作用し,将来の薬物開発に情報を与えます.
科学分野:
- 生物化学
- 構造生物学
- 薬理学について
背景:
- 生まれながらの高インスリン症 (HI) は,過剰なインスリン生成を引き起こす珍しい遺伝疾患です.
- インスリン受容体 (IR) 抗薬は,HIに対する潜在的な治療薬である.
- S961やIns-AC-S2のようなペプチドは,IRのインスリン結合部位 (部位1と部位2) を標的にする.
研究 の 目的:
- 冷凍電子顕微鏡 (cryo-EM) を用いてS961とIns-AC-S2によるIR対抗性の構造的基礎を解明する.
- 双価リガンドにおける結合モジュールの順序が,IRアゴニストまたはアンタゴニストの活動にどのように影響するかを理解する.
- S961とIns-AC-S2の結合メカニズムにおける構造的違いを特定する.
主な方法:
- S961とIns-AC-S2に結合したIRの構造を決定するための冷凍電子顕微鏡 (冷凍-EM)
- リガンド受容体相互作用の比較構造分析
主要な成果:
- Cryo-EM構造は,S961とIns-AC-S2が不活性なIR形状に結合することを明らかにし,それらの敵対的な効果を説明します.
- サイト1とサイト2の結合モジュールの順番は,二価リガンドがIRアゴニストかアンタゴニストとして作用するかを決定する.
- 異なる結合メカニズムが観察された.S961はαCTを位移し,Ins- AC- S2はそれを誘導し,新しい結合インターフェースを明らかにした.
結論:
- IRアンタゴニストの結合メカニズムに関する構造的な洞察は,新しいHI治療法の開発のための基盤を提供します.
- リガンド受容体の相互作用を理解することは,標的型IR調節器の設計に不可欠です.
- αCTと新しい結合インターフェースの異なる関与は,S961とIns-AC-S2の結合の主要な違いを強調する.
関連する概念動画
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
The Two-State Receptor Model
2.4K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.4K
Ligand Binding Sites
13.1K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
13.1K
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Insulin: Biosynthesis, Chemistry, and Preparation
518
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
518


